Drugs & Targets FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC June 27, 2025Vol.51 No.25
Drugs & Targets FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer June 27, 2025Vol.51 No.25
Drugs & Targets CHMP adopts positive opinion of Sarclisa + SOC for transplant-eligible newly diagnosed MM June 27, 2025Vol.51 No.25
Drugs & Targets CHMP adopts positive opinion of cabozantinib for previously treated advanced neuroendocrine tumors June 27, 2025Vol.51 No.25
Drugs & Targets FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC June 20, 2025Vol.51 No.24
Drugs & Targets FDA approves tablet formulation of Brukinsa for five approved indications June 13, 2025Vol.51 No.23
Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
Drugs & Targets SU2C, SandboxAQ collaborate to accelerate treatment innovation June 13, 2025Vol.51 No.23
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
